Clinical Trial: FHND1002 for ALS Treatment: Phase 2

U.S., Aug. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07138014) titled 'FHND1002 for ALS Treatment: Phase 2' on Aug. 15.

Brief Summary: This is a Phase II clinical trial evaluating the effectiveness and safety of an investigational drug, FHND1002 granules, in adults with Amyotrophic Lateral Sclerosis (ALS).

The main goals are:

To determine if FHND1002 can slow the progression of ALS compared to a placebo.

To assess the safety and tolerability of two different doses of FHND1002 (100mg and 200mg) in ALS patients.

Approximately 180 participants will be randomly assigned (like flipping a coin) to one of three groups:

FHND1002 100mg once daily

FHND1002 200mg once daily

Placebo (an inactive substance) ...